Syngene International Limited (BOM:539268)
451.85
+14.25 (3.26%)
At close: Nov 20, 2026
Syngene International Revenue
Syngene International had revenue of 8.33B INR in the quarter ending September 30, 2026, a decrease of -8.55%. This brings the company's total for the last twelve months to 35.22B, down -5.99% year-over-year. In the fiscal year ending March 31, 2026, Syngene International had annual revenue of 37.39B with 2.64% growth.
Revenue (ttm)
35.22B
Revenue Growth
-5.99%
P/S Ratio
5.11
Revenue / Employee
5.26M
Employees
6,692
Market Cap
179.82B
Revenue by Geography
- United States of America 23.48B 62.8%
- Europe 11.46B 30.7%
- Rest of The World 1.46B 3.9%
- India 981.00M 2.6%
Fiscal year ended Mar 31, 2026 See the full Syngene International breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 37.39B | 963.00M | 2.64% |
| Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
| Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
| Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
| Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 616.31B |
| Apollo Hospitals Enterprise | 278.52B |
| Divi's Laboratories | 121.91B |
| Lenskart Solutions | 103.83B |
| Syngene International | 35.22B |
| Alivus Life Sciences | 26.84B |
| Pfizer | 26.54B |
| Dr. Agarwal's Health Care | 23.63B |
Syngene International News
- 25 days ago - Syngene International Transcript: Q2 26/27 - Transcripts
- 25 days ago - Syngene International Quarterly report: Q2 2027 - Filings
- 25 days ago - Syngene International Slides: Q2 2027 - Filings
- 3 months ago - Syngene International Transcript: Q1 26/27 - Transcripts
- 3 months ago - Syngene International Quarterly report: Q1 2027 - Filings
- 3 months ago - Syngene International Slides: Q1 2027 - Filings
- 4 months ago - Syngene appoints Siddharth Mittal as Managing Director and CEO - Business Upturn
- 5 months ago - Syngene International announces 12.50% final dividend for FY26 - Business Upturn